Kelly Maloney
Concepts (352)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Precursor Cell Lymphoblastic Leukemia-Lymphoma | 36 | 2023 | 289 | 5.990 |
Why?
| Antineoplastic Combined Chemotherapy Protocols | 16 | 2022 | 1404 | 1.610 |
Why?
| Down Syndrome | 5 | 2019 | 329 | 1.600 |
Why?
| Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | 8 | 2021 | 57 | 1.370 |
Why?
| Asparaginase | 8 | 2020 | 32 | 1.040 |
Why?
| Burkitt Lymphoma | 2 | 2020 | 58 | 0.910 |
Why?
| Consolidation Chemotherapy | 2 | 2019 | 12 | 0.820 |
Why?
| Child | 63 | 2023 | 18649 | 0.810 |
Why?
| Leukemia, Myeloid, Acute | 5 | 2022 | 501 | 0.800 |
Why?
| Leukemia | 4 | 2021 | 207 | 0.680 |
Why?
| Child, Preschool | 44 | 2023 | 9714 | 0.680 |
Why?
| Mercaptopurine | 5 | 2017 | 18 | 0.630 |
Why?
| Oncogene Proteins, Fusion | 5 | 2021 | 201 | 0.590 |
Why?
| Disease-Free Survival | 10 | 2022 | 678 | 0.570 |
Why?
| Antineoplastic Agents | 7 | 2019 | 2016 | 0.560 |
Why?
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 2 | 2016 | 95 | 0.560 |
Why?
| Preleukemia | 1 | 2015 | 2 | 0.560 |
Why?
| Neoplasm Recurrence, Local | 3 | 2021 | 846 | 0.550 |
Why?
| Drug Hypersensitivity | 3 | 2017 | 86 | 0.540 |
Why?
| Leukemia, Monocytic, Acute | 1 | 2014 | 4 | 0.530 |
Why?
| Sarcoma, Myeloid | 1 | 2014 | 4 | 0.530 |
Why?
| Molecular Targeted Therapy | 3 | 2021 | 376 | 0.520 |
Why?
| Prognosis | 13 | 2021 | 3549 | 0.490 |
Why?
| Infant | 31 | 2023 | 8255 | 0.470 |
Why?
| Bone Marrow Transplantation | 1 | 2014 | 271 | 0.470 |
Why?
| Acute Kidney Injury | 1 | 2019 | 643 | 0.460 |
Why?
| Precursor T-Cell Lymphoblastic Leukemia-Lymphoma | 2 | 2023 | 18 | 0.460 |
Why?
| Neoplasm, Residual | 6 | 2021 | 93 | 0.450 |
Why?
| Erwinia | 2 | 2020 | 3 | 0.450 |
Why?
| Tumor Suppressor Proteins | 3 | 1999 | 281 | 0.440 |
Why?
| Chromosome Aberrations | 2 | 2022 | 129 | 0.440 |
Why?
| Neutropenia | 2 | 2022 | 128 | 0.430 |
Why?
| Adolescent | 36 | 2023 | 18902 | 0.430 |
Why?
| Hematopoietic Stem Cell Transplantation | 2 | 2019 | 563 | 0.420 |
Why?
| Stem Cell Transplantation | 3 | 2019 | 146 | 0.410 |
Why?
| Humans | 75 | 2023 | 117633 | 0.400 |
Why?
| Lymphoma, Large B-Cell, Diffuse | 2 | 2022 | 88 | 0.400 |
Why?
| Rhabdomyosarcoma | 1 | 2011 | 56 | 0.400 |
Why?
| Male | 53 | 2023 | 60403 | 0.400 |
Why?
| Sarcoma, Ewing | 1 | 2011 | 68 | 0.390 |
Why?
| Cell Cycle Proteins | 3 | 1999 | 569 | 0.390 |
Why?
| Ploidies | 2 | 2019 | 20 | 0.380 |
Why?
| Carrier Proteins | 3 | 1999 | 759 | 0.370 |
Why?
| Recurrence | 8 | 2022 | 1009 | 0.370 |
Why?
| Catheter-Related Infections | 2 | 2022 | 61 | 0.360 |
Why?
| Core Binding Factor Alpha 2 Subunit | 3 | 2021 | 26 | 0.360 |
Why?
| Genes, Tumor Suppressor | 2 | 1999 | 82 | 0.350 |
Why?
| Cyclophosphamide | 4 | 2019 | 236 | 0.350 |
Why?
| Catheterization, Central Venous | 2 | 2022 | 91 | 0.350 |
Why?
| Philadelphia Chromosome | 2 | 2018 | 15 | 0.330 |
Why?
| Female | 50 | 2023 | 63247 | 0.330 |
Why?
| Survival Rate | 7 | 2021 | 1807 | 0.300 |
Why?
| Vincristine | 4 | 2021 | 106 | 0.300 |
Why?
| Medication Adherence | 3 | 2017 | 553 | 0.300 |
Why?
| Trisomy | 2 | 2021 | 65 | 0.300 |
Why?
| Gene Deletion | 2 | 1998 | 368 | 0.300 |
Why?
| Antimetabolites, Antineoplastic | 2 | 2017 | 84 | 0.290 |
Why?
| Etoposide | 2 | 2019 | 161 | 0.290 |
Why?
| Neoplasm Proteins | 2 | 2018 | 411 | 0.280 |
Why?
| Anxiety | 3 | 2016 | 867 | 0.260 |
Why?
| Cyclin-Dependent Kinase Inhibitor p16 | 3 | 1999 | 73 | 0.260 |
Why?
| Treatment Outcome | 11 | 2022 | 9353 | 0.240 |
Why?
| Young Adult | 13 | 2023 | 11077 | 0.240 |
Why?
| Medical Oncology | 4 | 2022 | 221 | 0.240 |
Why?
| Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2023 | 53 | 0.230 |
Why?
| Gene Rearrangement | 3 | 2019 | 157 | 0.230 |
Why?
| Leukemia, Myelomonocytic, Juvenile | 1 | 2022 | 2 | 0.230 |
Why?
| Induction Chemotherapy | 2 | 2019 | 56 | 0.230 |
Why?
| Polyethylene Glycols | 5 | 2020 | 572 | 0.230 |
Why?
| Central Venous Catheters | 1 | 2022 | 35 | 0.220 |
Why?
| Doxorubicin | 2 | 2022 | 305 | 0.220 |
Why?
| Lymphoma | 1 | 2023 | 180 | 0.220 |
Why?
| Prednisone | 2 | 2019 | 250 | 0.210 |
Why?
| Lung Neoplasms | 1 | 2014 | 2171 | 0.210 |
Why?
| Program Evaluation | 2 | 2017 | 870 | 0.210 |
Why?
| Polymorphism, Single Nucleotide | 3 | 2017 | 1777 | 0.200 |
Why?
| Adult | 21 | 2023 | 32118 | 0.200 |
Why?
| Translocation, Genetic | 2 | 2013 | 99 | 0.200 |
Why?
| Bacterial Infections | 1 | 2022 | 220 | 0.200 |
Why?
| Maintenance Chemotherapy | 2 | 2017 | 25 | 0.200 |
Why?
| Risk Factors | 11 | 2022 | 9124 | 0.190 |
Why?
| Diploidy | 1 | 2019 | 11 | 0.190 |
Why?
| Immunocompromised Host | 1 | 2021 | 210 | 0.190 |
Why?
| Genes, p16 | 1 | 1999 | 20 | 0.180 |
Why?
| Antibodies, Bispecific | 1 | 2019 | 29 | 0.180 |
Why?
| Prospective Studies | 9 | 2022 | 6422 | 0.180 |
Why?
| Hyperglycemia | 1 | 2023 | 330 | 0.180 |
Why?
| PAX5 Transcription Factor | 1 | 2019 | 27 | 0.180 |
Why?
| Myelodysplastic Syndromes | 1 | 2020 | 115 | 0.180 |
Why?
| Chromosomes, Human, Pair 19 | 1 | 1998 | 24 | 0.180 |
Why?
| Chromosomes, Human, Pair 17 | 1 | 1998 | 48 | 0.180 |
Why?
| Rituximab | 1 | 2019 | 171 | 0.170 |
Why?
| Mutagenesis | 1 | 1999 | 175 | 0.170 |
Why?
| Chromosomes, Human, Pair 1 | 1 | 1998 | 66 | 0.170 |
Why?
| Prostate-Specific Antigen | 2 | 2009 | 164 | 0.170 |
Why?
| Substance Withdrawal Syndrome | 1 | 2020 | 185 | 0.170 |
Why?
| Patient Safety | 1 | 2021 | 310 | 0.160 |
Why?
| Family Relations | 2 | 2016 | 79 | 0.160 |
Why?
| Quality of Life | 2 | 2021 | 2354 | 0.160 |
Why?
| Oncologists | 1 | 2017 | 28 | 0.160 |
Why?
| Proto-Oncogenes | 1 | 1997 | 28 | 0.160 |
Why?
| Thionucleotides | 1 | 2017 | 34 | 0.160 |
Why?
| Thioguanine | 1 | 2017 | 21 | 0.160 |
Why?
| Apyrase | 1 | 2017 | 14 | 0.160 |
Why?
| Retrospective Studies | 9 | 2023 | 12331 | 0.160 |
Why?
| Blast Crisis | 1 | 2016 | 19 | 0.150 |
Why?
| Genomics | 2 | 2022 | 534 | 0.150 |
Why?
| Carboxypeptidases A | 1 | 2016 | 2 | 0.150 |
Why?
| Follow-Up Studies | 6 | 2021 | 4911 | 0.150 |
Why?
| Sepsis | 1 | 2022 | 491 | 0.150 |
Why?
| Pediatricians | 1 | 2017 | 110 | 0.150 |
Why?
| Depression | 2 | 2016 | 1196 | 0.150 |
Why?
| Mentoring | 1 | 2017 | 89 | 0.150 |
Why?
| Osteonecrosis | 1 | 2015 | 20 | 0.140 |
Why?
| Mentors | 2 | 2017 | 156 | 0.140 |
Why?
| Nausea | 1 | 2016 | 108 | 0.140 |
Why?
| Central Nervous System Neoplasms | 1 | 2017 | 126 | 0.140 |
Why?
| Gene Expression Regulation, Enzymologic | 1 | 2017 | 309 | 0.140 |
Why?
| Adrenal Cortex Hormones | 1 | 2019 | 517 | 0.140 |
Why?
| Dexamethasone | 4 | 2021 | 305 | 0.140 |
Why?
| Pancreatitis | 1 | 2016 | 112 | 0.140 |
Why?
| Longitudinal Studies | 7 | 2016 | 2668 | 0.140 |
Why?
| Mutation | 4 | 2022 | 3409 | 0.140 |
Why?
| Fusion Proteins, bcr-abl | 2 | 2016 | 62 | 0.130 |
Why?
| Bacteremia | 1 | 2016 | 160 | 0.130 |
Why?
| Monitoring, Physiologic | 1 | 2017 | 269 | 0.130 |
Why?
| High-Throughput Nucleotide Sequencing | 1 | 2017 | 423 | 0.130 |
Why?
| Cyclin-Dependent Kinase Inhibitor p15 | 3 | 1999 | 14 | 0.130 |
Why?
| Myeloid-Lymphoid Leukemia Protein | 2 | 2010 | 66 | 0.130 |
Why?
| Antigens, CD | 1 | 2017 | 470 | 0.130 |
Why?
| Cross Infection | 1 | 2016 | 199 | 0.130 |
Why?
| Histone-Lysine N-Methyltransferase | 2 | 2010 | 99 | 0.130 |
Why?
| Flow Cytometry | 1 | 2018 | 1132 | 0.130 |
Why?
| Repressor Proteins | 1 | 1997 | 398 | 0.130 |
Why?
| Immunotherapy | 1 | 2018 | 477 | 0.130 |
Why?
| Venous Thromboembolism | 1 | 2017 | 206 | 0.130 |
Why?
| Life Change Events | 1 | 2014 | 134 | 0.120 |
Why?
| Chromosomes, Human, Pair 21 | 1 | 2013 | 29 | 0.120 |
Why?
| Pediatrics | 3 | 2021 | 1021 | 0.120 |
Why?
| Quality Improvement | 1 | 2021 | 940 | 0.120 |
Why?
| DNA-Binding Proteins | 2 | 1998 | 1384 | 0.120 |
Why?
| Leukemia, Megakaryoblastic, Acute | 1 | 2012 | 8 | 0.120 |
Why?
| Self Report | 1 | 2017 | 715 | 0.120 |
Why?
| Karyotyping | 3 | 2019 | 106 | 0.110 |
Why?
| Myeloproliferative Disorders | 1 | 2012 | 25 | 0.110 |
Why?
| Transcription Factors | 2 | 1998 | 1623 | 0.110 |
Why?
| Arabinonucleosides | 1 | 2011 | 9 | 0.110 |
Why?
| Adenine Nucleotides | 1 | 2011 | 21 | 0.110 |
Why?
| Contraindications | 1 | 2012 | 93 | 0.110 |
Why?
| Antibodies, Monoclonal | 1 | 2018 | 1267 | 0.110 |
Why?
| Cohort Studies | 5 | 2021 | 5112 | 0.100 |
Why?
| Prostatic Neoplasms | 2 | 2009 | 977 | 0.100 |
Why?
| Chromosomes, Human, Pair 10 | 1 | 2010 | 17 | 0.100 |
Why?
| Chromosomes, Human, Pair 4 | 1 | 2010 | 33 | 0.100 |
Why?
| Parents | 2 | 2016 | 1163 | 0.100 |
Why?
| T-Lymphocytes | 1 | 2018 | 1793 | 0.100 |
Why?
| Pain | 1 | 2016 | 796 | 0.090 |
Why?
| Multivariate Analysis | 4 | 2015 | 1584 | 0.090 |
Why?
| Bloom Syndrome | 1 | 1988 | 1 | 0.090 |
Why?
| Prostatectomy | 1 | 2009 | 113 | 0.090 |
Why?
| Age Factors | 8 | 2019 | 3223 | 0.090 |
Why?
| Neoplasm Metastasis | 1 | 2011 | 593 | 0.090 |
Why?
| Juxtaglomerular Apparatus | 1 | 2007 | 1 | 0.080 |
Why?
| Gene Expression Regulation, Leukemic | 2 | 2016 | 54 | 0.080 |
Why?
| Polymerase Chain Reaction | 1 | 2010 | 1016 | 0.080 |
Why?
| Blood Coagulation | 1 | 2008 | 200 | 0.080 |
Why?
| Drug Administration Schedule | 2 | 2017 | 780 | 0.070 |
Why?
| Methotrexate | 2 | 2017 | 243 | 0.070 |
Why?
| Stress, Psychological | 1 | 2014 | 1149 | 0.070 |
Why?
| Remission Induction | 2 | 2019 | 264 | 0.070 |
Why?
| Drug Monitoring | 2 | 2017 | 188 | 0.070 |
Why?
| Acute Disease | 2 | 2019 | 983 | 0.070 |
Why?
| Personal Satisfaction | 2 | 2017 | 183 | 0.060 |
Why?
| Administration, Oral | 2 | 2017 | 786 | 0.060 |
Why?
| Genetic Variation | 1 | 1988 | 801 | 0.060 |
Why?
| Kidney Neoplasms | 1 | 2007 | 342 | 0.060 |
Why?
| Randomized Controlled Trials as Topic | 2 | 2020 | 1209 | 0.060 |
Why?
| Disease Progression | 2 | 2021 | 2541 | 0.060 |
Why?
| Transcriptome | 2 | 2019 | 731 | 0.060 |
Why?
| Proto-Oncogene Proteins c-cbl | 1 | 2022 | 14 | 0.060 |
Why?
| Incidence | 2 | 2019 | 2504 | 0.050 |
Why?
| Exome | 1 | 2022 | 163 | 0.050 |
Why?
| Drug Therapy | 1 | 2021 | 74 | 0.050 |
Why?
| Diarrhea | 2 | 1999 | 172 | 0.050 |
Why?
| Bone Marrow | 1 | 2022 | 255 | 0.050 |
Why?
| Risk Assessment | 3 | 2017 | 3208 | 0.050 |
Why?
| Endocrine Glands | 1 | 1979 | 17 | 0.050 |
Why?
| Genome-Wide Association Study | 2 | 2016 | 1036 | 0.050 |
Why?
| Surveys and Questionnaires | 3 | 2017 | 4842 | 0.050 |
Why?
| Blood Cell Count | 1 | 1999 | 58 | 0.050 |
Why?
| Azacitidine | 1 | 2020 | 105 | 0.050 |
Why?
| Viral Load | 1 | 2021 | 416 | 0.050 |
Why?
| Chromosomes, Human | 1 | 2019 | 40 | 0.050 |
Why?
| Loss of Heterozygosity | 1 | 1999 | 35 | 0.050 |
Why?
| Mosaicism | 1 | 2019 | 55 | 0.050 |
Why?
| Cytogenetic Analysis | 1 | 2019 | 29 | 0.050 |
Why?
| Bridged Bicyclo Compounds, Heterocyclic | 1 | 2020 | 149 | 0.050 |
Why?
| Interviews as Topic | 1 | 2021 | 614 | 0.050 |
Why?
| Disinfectants | 1 | 1999 | 28 | 0.040 |
Why?
| Infant, Newborn | 4 | 2019 | 5230 | 0.040 |
Why?
| Chromosomes | 1 | 2019 | 78 | 0.040 |
Why?
| Sequence Deletion | 1 | 1999 | 180 | 0.040 |
Why?
| National Cancer Institute (U.S.) | 1 | 2018 | 40 | 0.040 |
Why?
| United States | 4 | 2021 | 12768 | 0.040 |
Why?
| Escherichia coli O157 | 1 | 1998 | 9 | 0.040 |
Why?
| Hypertension | 1 | 2007 | 1202 | 0.040 |
Why?
| Overweight | 1 | 2023 | 495 | 0.040 |
Why?
| Methylation | 1 | 1998 | 216 | 0.040 |
Why?
| Feasibility Studies | 1 | 2021 | 766 | 0.040 |
Why?
| Community Participation | 1 | 1999 | 120 | 0.040 |
Why?
| Family | 1 | 2021 | 567 | 0.040 |
Why?
| Erythrocyte Count | 1 | 2017 | 18 | 0.040 |
Why?
| Glucose | 1 | 2023 | 926 | 0.040 |
Why?
| Food-Drug Interactions | 1 | 2017 | 7 | 0.040 |
Why?
| Leucovorin | 1 | 2017 | 47 | 0.040 |
Why?
| Public Health Surveillance | 1 | 2017 | 63 | 0.040 |
Why?
| Biopsy | 1 | 2021 | 1070 | 0.040 |
Why?
| Injections, Intramuscular | 1 | 2017 | 125 | 0.040 |
Why?
| Water Purification | 1 | 1999 | 115 | 0.040 |
Why?
| Genetic Predisposition to Disease | 2 | 2017 | 2206 | 0.040 |
Why?
| Career Mobility | 1 | 2017 | 71 | 0.040 |
Why?
| Escherichia coli Infections | 1 | 1998 | 125 | 0.040 |
Why?
| Proto-Oncogene Proteins c-ets | 1 | 1997 | 52 | 0.040 |
Why?
| Qualitative Research | 1 | 2021 | 856 | 0.040 |
Why?
| Dairy Products | 1 | 2017 | 33 | 0.040 |
Why?
| Cranial Irradiation | 1 | 2017 | 63 | 0.040 |
Why?
| Cerebrospinal Fluid | 1 | 2017 | 93 | 0.040 |
Why?
| MEF2 Transcription Factors | 1 | 2016 | 58 | 0.040 |
Why?
| Sulfonamides | 1 | 2020 | 451 | 0.040 |
Why?
| Infusions, Intravenous | 1 | 2017 | 393 | 0.040 |
Why?
| Methyltransferases | 1 | 2017 | 59 | 0.040 |
Why?
| NIH 3T3 Cells | 1 | 2016 | 133 | 0.040 |
Why?
| Leukocyte Count | 1 | 2017 | 328 | 0.040 |
Why?
| Luciferases | 1 | 2016 | 148 | 0.040 |
Why?
| Methyl Ethers | 1 | 1996 | 10 | 0.040 |
Why?
| Anesthetics, Inhalation | 1 | 1996 | 18 | 0.040 |
Why?
| Ethers | 1 | 1996 | 15 | 0.040 |
Why?
| Breast Neoplasms | 5 | 1979 | 1929 | 0.040 |
Why?
| Middle Aged | 10 | 2019 | 28659 | 0.040 |
Why?
| Bone Morphogenetic Protein 7 | 1 | 2015 | 10 | 0.040 |
Why?
| Fluorides | 1 | 1996 | 49 | 0.040 |
Why?
| Cytarabine | 1 | 2016 | 59 | 0.040 |
Why?
| Health Education | 1 | 1999 | 342 | 0.040 |
Why?
| Alternative Splicing | 1 | 2017 | 201 | 0.030 |
Why?
| Genotype | 3 | 2017 | 1825 | 0.030 |
Why?
| DNA Methylation | 1 | 1999 | 441 | 0.030 |
Why?
| Severity of Illness Index | 2 | 2017 | 2884 | 0.030 |
Why?
| Histone Deacetylase Inhibitors | 1 | 2016 | 209 | 0.030 |
Why?
| Intensive Care Units, Pediatric | 1 | 2016 | 197 | 0.030 |
Why?
| Disease Management | 1 | 2019 | 603 | 0.030 |
Why?
| Homeodomain Proteins | 1 | 1998 | 496 | 0.030 |
Why?
| HEK293 Cells | 1 | 2017 | 656 | 0.030 |
Why?
| Biomarkers, Tumor | 1 | 2021 | 1049 | 0.030 |
Why?
| Aged | 9 | 2019 | 20249 | 0.030 |
Why?
| Sequence Analysis, RNA | 1 | 2016 | 413 | 0.030 |
Why?
| Promoter Regions, Genetic | 1 | 1999 | 1220 | 0.030 |
Why?
| Algorithms | 1 | 2021 | 1550 | 0.030 |
Why?
| Income | 1 | 2014 | 174 | 0.030 |
Why?
| Blood Glucose | 1 | 2023 | 1904 | 0.030 |
Why?
| Demography | 1 | 2014 | 279 | 0.030 |
Why?
| Marriage | 1 | 2014 | 111 | 0.030 |
Why?
| Behavior | 1 | 2014 | 107 | 0.030 |
Why?
| Psychomotor Agitation | 1 | 2014 | 79 | 0.030 |
Why?
| Base Sequence | 1 | 2016 | 2171 | 0.030 |
Why?
| In Situ Hybridization, Fluorescence | 1 | 2013 | 328 | 0.030 |
Why?
| Clinical Trials as Topic | 1 | 2017 | 999 | 0.030 |
Why?
| Case-Control Studies | 2 | 2016 | 3269 | 0.030 |
Why?
| Odds Ratio | 1 | 2015 | 1038 | 0.030 |
Why?
| Nucleoside Transport Proteins | 1 | 2011 | 4 | 0.030 |
Why?
| Aggression | 1 | 2014 | 204 | 0.030 |
Why?
| Erythrocytes | 1 | 2017 | 610 | 0.030 |
Why?
| Antineoplastic Agents, Alkylating | 1 | 2011 | 65 | 0.030 |
Why?
| Regression Analysis | 1 | 2014 | 1072 | 0.030 |
Why?
| Escherichia coli | 1 | 2015 | 789 | 0.030 |
Why?
| Mice | 2 | 2019 | 15537 | 0.030 |
Why?
| Time Factors | 2 | 2015 | 6906 | 0.030 |
Why?
| Bacteria | 1 | 2016 | 671 | 0.020 |
Why?
| Antineoplastic Agents, Phytogenic | 1 | 2011 | 193 | 0.020 |
Why?
| Survival Analysis | 1 | 2013 | 1358 | 0.020 |
Why?
| Logistic Models | 1 | 2015 | 2018 | 0.020 |
Why?
| Obesity | 1 | 2023 | 2711 | 0.020 |
Why?
| Prevalence | 1 | 2016 | 2438 | 0.020 |
Why?
| Emotions | 1 | 2014 | 473 | 0.020 |
Why?
| Kaplan-Meier Estimate | 1 | 2011 | 896 | 0.020 |
Why?
| Sister Chromatid Exchange | 1 | 1988 | 4 | 0.020 |
Why?
| Mice, Inbred C57BL | 1 | 2019 | 5136 | 0.020 |
Why?
| Genetic Complementation Test | 1 | 1988 | 65 | 0.020 |
Why?
| Cell Fusion | 1 | 1988 | 54 | 0.020 |
Why?
| Protein C | 1 | 2008 | 38 | 0.020 |
Why?
| Water Microbiology | 2 | 1999 | 76 | 0.020 |
Why?
| Antithrombins | 1 | 2008 | 58 | 0.020 |
Why?
| Plasminogen Activator Inhibitor 1 | 1 | 2008 | 93 | 0.020 |
Why?
| Fibrinogen | 1 | 2008 | 161 | 0.020 |
Why?
| Genetic Markers | 1 | 1988 | 349 | 0.020 |
Why?
| Renin-Angiotensin System | 1 | 2007 | 84 | 0.020 |
Why?
| Biomarkers | 1 | 2017 | 3574 | 0.020 |
Why?
| Biopsy, Needle | 1 | 2007 | 193 | 0.020 |
Why?
| Rare Diseases | 1 | 2007 | 87 | 0.020 |
Why?
| Transplantation, Homologous | 1 | 2008 | 464 | 0.020 |
Why?
| Blood Pressure Determination | 1 | 2007 | 130 | 0.020 |
Why?
| Nephrectomy | 1 | 2007 | 160 | 0.020 |
Why?
| Animals | 2 | 2019 | 34350 | 0.020 |
Why?
| RNA, Messenger | 1 | 2011 | 2757 | 0.020 |
Why?
| Immunohistochemistry | 1 | 2007 | 1756 | 0.010 |
Why?
| Cell Line | 1 | 1988 | 2832 | 0.010 |
Why?
| Estriol | 1 | 1979 | 6 | 0.010 |
Why?
| Menstruation | 1 | 1979 | 34 | 0.010 |
Why?
| Estrone | 1 | 1979 | 32 | 0.010 |
Why?
| Prolactin | 1 | 1979 | 107 | 0.010 |
Why?
| Bolivia | 1 | 1999 | 46 | 0.010 |
Why?
| Luteinizing Hormone | 1 | 1979 | 187 | 0.010 |
Why?
| Follicle Stimulating Hormone | 1 | 1979 | 220 | 0.010 |
Why?
| Restaurants | 1 | 1998 | 14 | 0.010 |
Why?
| Food Handling | 1 | 1998 | 23 | 0.010 |
Why?
| Swimming | 1 | 1998 | 51 | 0.010 |
Why?
| Progesterone | 1 | 1979 | 258 | 0.010 |
Why?
| Water Supply | 1 | 1998 | 73 | 0.010 |
Why?
| Disease Transmission, Infectious | 1 | 1998 | 61 | 0.010 |
Why?
| Meat | 1 | 1998 | 65 | 0.010 |
Why?
| Estradiol | 1 | 1979 | 465 | 0.010 |
Why?
| Halothane | 1 | 1996 | 6 | 0.010 |
Why?
| Feces | 1 | 1998 | 366 | 0.010 |
Why?
| Population Surveillance | 1 | 1999 | 449 | 0.010 |
Why?
| Analysis of Variance | 1 | 1999 | 1451 | 0.010 |
Why?
| Ovarian Neoplasms | 1 | 1978 | 386 | 0.010 |
Why?
| Risk | 4 | 1978 | 926 | 0.010 |
Why?
| Pedigree | 3 | 1978 | 471 | 0.010 |
Why?
| Kidney | 1 | 1996 | 1237 | 0.010 |
Why?
| Aged, 80 and over | 1 | 1999 | 6795 | 0.000 |
Why?
| Nebraska | 2 | 1976 | 6 | 0.000 |
Why?
| New York | 2 | 1976 | 113 | 0.000 |
Why?
| Genes | 1 | 1978 | 225 | 0.000 |
Why?
| Genetic Linkage | 1 | 1978 | 303 | 0.000 |
Why?
| Oncogenic Viruses | 1 | 1976 | 3 | 0.000 |
Why?
| Apocrine Glands | 1 | 1976 | 5 | 0.000 |
Why?
| Genetic Techniques | 1 | 1976 | 62 | 0.000 |
Why?
| Pheochromocytoma | 1 | 1976 | 52 | 0.000 |
Why?
| Klinefelter Syndrome | 1 | 1976 | 53 | 0.000 |
Why?
| Syndrome | 1 | 1976 | 352 | 0.000 |
Why?
| Pregnancy | 2 | 1978 | 5554 | 0.000 |
Why?
| Statistics as Topic | 1 | 1976 | 333 | 0.000 |
Why?
| HLA Antigens | 1 | 1976 | 213 | 0.000 |
Why?
| Sarcoma | 1 | 1976 | 131 | 0.000 |
Why?
| Abnormalities, Multiple | 1 | 1976 | 177 | 0.000 |
Why?
| Skin Diseases | 1 | 1976 | 157 | 0.000 |
Why?
| Thyroid Neoplasms | 1 | 1976 | 240 | 0.000 |
Why?
| Neoplasms | 2 | 1976 | 2139 | 0.000 |
Why?
| Sex Factors | 1 | 1978 | 1918 | 0.000 |
Why?
| Melanoma | 1 | 1976 | 703 | 0.000 |
Why?
| Phenotype | 1 | 1976 | 2875 | 0.000 |
Why?
| Brain Neoplasms | 1 | 1976 | 976 | 0.000 |
Why?
| Registries | 1 | 1976 | 1969 | 0.000 |
Why?
|
|
Maloney's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|